Trial Profile
A trial to study the effect of osimertinib on EGFR T790M resistance mutation in non small cell lung cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2020
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Dec 2020 Results published in the Targeted Oncology
- 04 Aug 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology